Beneficial effects of the novel cholecystokinin agonist (pGlu-Gln)-CCK-8 in mouse models of obesity/diabetes

Diabetologia

Volumn 55, Issue 10, 2012, Pages 2747-2758

  Irwin, N ^a   Frizelle, P ^a   Montgomery, I A ^a   Moffett, R C ^a   O'Harte, F P M ^a   Flatt, P R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Cholecystokinin (CCK); Diabetes; Drug tolerance; Glucose tolerance; High fat; Insulin sensitivity; Obesity

Indexed keywords

CHOLECYSTOKININ; CHOLECYSTOKININ OCTAPEPTIDE; GLUCOSE; GLUTAMIC ACID; GLUTAMINE; INSULIN; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC OBESITY; DRUG DEGRADATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG TOLERANCE; ENERGY EXPENDITURE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; HISTOPATHOLOGY; IN VIVO STUDY; INSULIN SENSITIVITY; LIPID DIET; LIVER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SATIETY; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT REDUCTION;

ANIMALS; CHOLECYSTOKININ; COMORBIDITY; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; GLUCOSE; HOMEOSTASIS; INSULIN RESISTANCE; MALE; MICE; MICE, OBESE; OBESITY; SINCALIDE;

EID: 84866074718     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-012-2654-6     Document Type: Article

References (37)

1. Ivy AC, Oldberg E (1928) A hormone mechanism for gallbladder contraction and evacuation. Am J Physiol 65:599-613
2. Verbaeys I, León-Tamariz F, Buyse J, de Cuyper M, Pottel H, van Boven M et al (2007) PEGylated cholecystokinin prolongs satiation in rats: dose dependency and receptor involvement. Br J Pharmacol 152:396-403 (Pubitemid 47511254)
3. Cantor P, Rehfeld JF (1989) Cholecystokinin in pig plasma: release of components devoid of a bioactive COOH-terminus. Am J Physiol 256:G53-G61
4. Rehfeld JF, Friis-Hansen L, Goetze JP, Hansen TV (2007) The biology of cholecystokinin and gastrin peptides. Curr Top Med Chem 7:1154-1165 (Pubitemid 47040503)
5. Dufresne M, Seva C, Fourmy D (2006) Cholecystokinin and gastrin receptors. Physiol Rev 86:805-847 (Pubitemid 44033383)
6. Liddle RA (1994) Cholecystokinin. In: Walsh JH, Dockray GJ (eds) Gut peptides biochemistry and physiology. Raven, New York, pp 175-216
7. Lavine JA, Raess PW, Stapleton DS, Rabaglia ME, Suhonen JI, Schueler KL et al (2010) Cholecystokinin is up-regulated in obese mouse islets and expands beta-cell mass by increasing beta-cell survival. Endocrinology 151:3577-3588
8. Flatt PR, Bailey CJ, Green BD (2009) Recent advances in antidiabetic drug therapies targeting the enteroinsular axis. Curr Drug Metab 10:125-137
9. Holst JJ, Vilsboll T, Deacon CF (2009) The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 297:127-136
10. Rehfeld JF (2011) Incretin physiology beyond glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: cholecystokinin and gastrin peptides. Acta Physiol (Oxf) 201:405-411
11. Verbaeys I, León-Tamariz F, Buyse J, Decuypere E, Pottel H, Cokelaere M (2009) Lack of tolerance development with long-term administration of PEGylated cholecystokinin. Peptides 30:699-704
12. Verbaeys I, León-Tamariz F, Pottel H, Decuypere E, Swennen Q, Cokelaere M (2008) PEGylated cholecystokinin is more potent in inducing anorexia than conditioned taste aversion in rats. Br J Pharmacol 155:417-423
13. Peter SA, D'Amato M, Beglinger C (2006) CCK1 antagonists: are they ready for clinical use? Dig Dis 24:70-82
14. Hoffmann P, Eberlein GA, Reeve JR Jr, Bünte RH, Grandt D, Goebell H et al (1993) Comparison of clearance and metabolism of infused cholecystokinins 8 and 58 in dogs. Gastroenterology 105:1732-1736 (Pubitemid 24002790)
15. Migaud M, Durieux C, Viereck J, Soroca-Lucas E, Fournié-Zaluski MC, Roques BP (1996) The in vivo metabolism of cholecystokinin (CCK-8) is essentially ensured by aminopeptidase A. Peptides 17:601-607 (Pubitemid 26238392)
16. O'Harte FP, Mooney MH, Kelly CM, Flatt PR (1998) Glycated cholecystokinin-8 has an enhanced satiating activity and is protected against enzymatic degradation. Diabetes 47:1619-1624 (Pubitemid 28445351)
17. Kerr BD, Irwin N, O'Harte FP, Bailey CJ, Flatt PR, Gault VA (2009) Fatty acid derivatised analogs of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Biochem Pharmacol 78:1008-1016
18. McClenaghan NH, Barnett CR, Ah-Sing E, Abdel-Wahab YH, O'Harte FP, Yoon TW et al (1996) Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion. Diabetes 45:1132-1140 (Pubitemid 26260168)
19. Flatt PR, Bailey CJ (1981) Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia 20:573-577 (Pubitemid 11096955)
20. 3)GIP improves metabolic status in high-fat-fed mice. Diabetes Obes Metab 12:744-751
21. Bailey CJ, Flatt PR, Atkins TW (1982) Influence of genetic background and age on the expression of the obese hyperglycemic syndrome in Aston ob/ob mice. Int J Obes 6:11-21 (Pubitemid 12157286)
22. Lo CM, Obici S, Dong HH, Haas M, Lou D, Kim DH et al (2011) Impaired insulin secretion and enhanced insulin sensitivity in cholecystokinin-deficient mice. Diabetes 60:2000-2007
23. Ali S, Lamont BJ, Charron MJ, Drucker DJ (2011) Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis. J Clin Invest 121:1917-1929
24. Layden BT, Durai V, Newman MV, Marinelarena AM, Ahn CW, Feng G et al (2010) Regulation of pancreatic islet gene expression in mouse islets by pregnancy. J Endocrinol 207:265-279
25. Mack CM, Moore CX, Jodka CM, Bhavsar S, Wilson JK, Hoyt JA et al (2006) Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. Int J Obes (Lond) 30:1332-1340 (Pubitemid 44306514)
26. Chen H, Kent S, Morris MJ (2006) Is the CCK2 receptor essential for normal regulation of body weight and adiposity? Eur J Neurosci 24:1427-1433 (Pubitemid 44401665)
27. Bradwejn J (1993) Neurobiological investigations into the role of cholecystokinin in panic disorder. J Psychiatry Neurosci 18:178-188 (Pubitemid 23255883)
28. Wang H, Wong PT, Spiess J, Zhu YZ (2005) Cholecystokinin-2 (CCK2) receptor-mediated anxiety-like behaviors in rats. Neurosci Biobehav Rev 29:1361-1373 (Pubitemid 41446905)
29. Jordan J, Greenway FL, Leiter LA, Li Z, Jacobson P, Murphy K et al (2008) Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients. Clin Pharmacol Ther 83:281-287
30. Roses AD (2004) Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev Genet 5:645-656 (Pubitemid 39150121)
31. Roses AD (2009) Stimulation of cholecystokinin-A receptors with Gl181771X a failed clinical trial that did not test the pharmacogenetic hypothesis for reduction of food intake. Clin Pharmacol Ther 85:362-365
32. Neary MT, Batterham RL (2009) Gut hormones: implications for the treatment of obesity. Pharmacol Ther 124:44-56
33. Ahrén B, Holst JJ, Efendic S (2000) Antidiabetogenic action of cholecystokinin-8 in type 2 diabetes. J Clin Endocrinol Metab 85:1043-1048 (Pubitemid 32269347)
34. Mineka S, Snowdon CT (1978) Inconsistency and possible habituation of CCK-induced satiety. Physiol Behav 21:65-72 (Pubitemid 8380813)
35. Crawley JN, Beinfeld MC (1983) Rapid development of tolerance to the behavioural actions of cholecystokinin. Nature 302:703-706 (Pubitemid 13120271)
36. West DB, Greenwood MR, Marshall KA, Woods SC (1987) Lithium chloride, cholecystokinin and meal patterns: evidence that cholecystokinin suppresses meal size in rats without causing malaise. Appetite 8:221-227
37. Ahrén B (2011) The future of incretin-based therapy: novel avenues-novel targets. Diabetes Obes Metab 13(Suppl 1):158-166